Dr. Rose obtained his B.S.E. in Biomedical Engineering at the University of Michigan in 2006 and his M.D. from Wayne State University School of Medicine in 2010. He went on to Duke University Medical Center in North Carolina for his Internal Medicine Residency and the University of Pittsburgh for Pulmonary & Critical Care Medicine Fellowship. He obtained his MBA from Carnegie Mellon University’s Tepper School of Business in 2017 in a novel Biomedical Entrepreneurship Track. He is currently an Assistant Professor of Medicine at the University of Pittsburgh. He is part of the scientific team that developed Globin Solution’s lead compound, recombinant neuroglobin. His academic research work focuses on understanding the molecular mechanisms of CO poisoning and the effects of carbon monoxide poisoning on patients. He continues to serve as an attending physician in the intensive care unit. Dr Rose cofounded Globin Solutions, Inc., along with Drs. Gladwin and Tejero in 2017.

Dr Tejero received his B.Sc. degree in Organic Chemistry in 1998 and his PhD in Biochemistry in 2004 from the University of Saragossa (Spain). In 2005 he joined Dr. Dennis Stuehr lab in the Cleveland Clinic for postdoctoral studies on Nitric Oxide Synthase structure and function. He moved to the Vascular Medicine Institute of the University of Pittsburgh in 2009 as a Research Associate to work with Dr. Mark Gladwin on heme proteins and nitrite metabolism. Since 2015, he is an Assistant Professor in the Department of Medicine of the University of Pittsburgh. His research is focused on the biology of heme proteins. His main research goals include: i) to understand the chemistry and biology of the reactions of nitrite with mammalian heme proteins; ii) to determine the cytoprotective mechanisms of the novel six-coordinate globins neuroglobin and cytoglobin, and iii) the development of heme-based antidotes for carbon monoxide poisoning. Dr Tejero cofounded Globin Solutions, Inc., along with Drs. Gladwin and Rose in 2017.

Dr. DeMartino earned his B.S. in chemistry from Wake Forest University and his Ph.D. in chemistry from the University of California, Santa Barbara in 2017 where he specialized in bioinorganic reaction mechanisms, chemical synthesis, and reaction kinetics involving small bioregulation molecules like nitric oxide (NO) and carbon monoxide (CO). In 2018, he joined Dr. Mark Gladwin’s group at the University of Pittsburgh for his postdoctoral work, where he focuses on the chemistry and translational research of heme-based proteins and models and their interactions with NO, CO, and nitrite. His current research interests specifically include a) the activation and metabolism of inorganic nitrite by hemoproteins; b) the determination of native substrates, redox chemistry, and functions of the hemoproteins cytoglobin and neuroglobin; c) and the development of hemoprotein-based therapeutics for CO poisoning. Dr. DeMartino joined Globin Solutions as a Research Director in 2021.

Lindsey Bocian joined the team as Program Administrator in March 2021. She earned her B.S. in Biology from Gannon University in 2011. She has experience as a project manager, laboratory manager, and laboratory technician.

Dr. Ed Branson is an experienced CMC operations executive who led the daily operations of seven GMP manufacturing organizations including cell culture, fermentation, vaccine and trans-dermal patch, transgenic plant, combination pulmonary drug/device and regenerative tissue manufacturing facilities. He managed pilot plants, directed production from preclinical through Phase III and brought five manufacturing facilities into GMP compliance.

Dr. Tilmann Brotz is a senior Development Sciences Consultant with over 15 years of experience in the biopharmaceutical industry leading toxicology, DMPK, in-vivo pharmacology, clinical pharmacology and diagnostic groups. He also has extensive experience with multiple clinical biomarker modalities (blood, histology, FDGPET and CT imaging). He is a CLSI FAST advisor and a member of the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation.

Dr. Mary Sherman is a skilled scientific advisor and program manager for late-stage Discovery through Phase III of drug development.  She manages programs/studies from late-stage Discovery through Phase III, including bioanalytical, drug metabolism, PK/TK, immunogenicity and regulatory requirements.  Additionally she provides support to both nonclinical and clinical studies.  Dr. Sherman has a strong reputation for critical thinking, relationship building, social intelligence, and clear communications that establishes bridges between scientific and non-scientific stakeholder coupled with a proven analysis and strategic perspective combined with marketing, operations, and R&D integration.

Ms. Damphousse has 20 years of experience in the biopharmaceutical industry with special training in Biotechnology Project Management. She has managed projects for Pharmadirections for over 7 years including support of both CMC and nonclinical IND enabling activities for small molecules and biologics. She provides project momentum to meet milestones through vendor, timeline, budget and meeting management. Ms. Damphousse also has 10 years of experience as an R&D scientist in both start-ups and big pharma.

Dr Gladwin received his M.D. from the University of Miami Honors Program in Medical Education in 1991. After completing his internship and chief residency at the Oregon Health Sciences University in Portland, Ore., he joined the NIH in 1995 as a critical care fellow in the Clinical Center. After completion of a clinical fellowship in pulmonary medicine at the University of Washington in Seattle, he returned for a research fellowship at the Critical Care Medicine Department, CC, under the mentorship of James Shelhamer, Frederick Ognibene, Alan Schechter, and Richard Cannon. He later served as the Chief of the Pulmonary and Vascular Medicine Branch within the NHLBI, NIH. He joined the University of Pittsburgh in 2008 and now serves as the Chair of the Department of Medicine since 2015 and the director of the Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute. Dr. Gladwin’s clinical research and expertise focuses on pulmonary hypertension and pulmonary complications of sickle cell disease.  He served as PI on the multi-center clinical trials Walk-PHASST (Pulmonary Hypertension and Sickle Sildenafil Therapy Trial) and DeNOVO (Delivery of NO for Vaso-Occlusive pain crisis in sickle cell disease).  He has served as a principal or associate investigator on more than 25 human subjects protocols and holds seven FDA INDs for the use of investigational therapeutic medications, including nitrite, carbon monoxide, L-NMMA, and sildenafil. He continues to serve as an attending physician in the intensive care unit. Dr Gladwin cofounded Globin Solutions, Inc., along with Drs. Rose and Tejero in 2017.

Dr. Rose obtained his B.S.E. in Biomedical Engineering at the University of Michigan in 2006 and his M.D. from Wayne State University School of Medicine in 2010. He went on to Duke University Medical Center in North Carolina for his Internal Medicine Residency and the University of Pittsburgh for Pulmonary & Critical Care Medicine Fellowship. He obtained his MBA from Carnegie Mellon University’s Tepper School of Business in 2017 in a novel Biomedical Entrepreneurship Track. He is currently an Assistant Professor of Medicine at the University of Pittsburgh. He is part of the scientific team that developed Globin Solution’s lead compound, recombinant neuroglobin. His academic research work focuses on understanding the molecular mechanisms of CO poisoning and the effects of carbon monoxide poisoning on patients. He continues to serve as an attending physician in the intensive care unit. Dr Rose cofounded Globin Solutions, Inc., along with Drs. Gladwin and Tejero in 2017.

Mr Wang received his MBA from Carnegie Mellon University’s Tepper School of Business, and both a bachelor’s of science in Engineering Physics and master’s of public policy from Tsinghua University. Throughout his career, Mr. Wang has led efforts for business development, quality control, new products, financial management, and business analytics in the life science industry. Mr Wang also currently serves as the chief financial officer of Innovatus Imaging, and was head of business analytics at Bayer Medical Care Multi Vendor Service.

Ms Cunicelli is currently Executive Vice President of UPMC Enterprises. Ms. Cunicelli has more than two decades of investment and advising experience in the life sciences industry. Ms. Cunicelli received an MBA in Finance from the University of San Francisco and holds a B.S. degree in Cognitive Psychology from Carnegie Mellon University. Ms. Cunicelli was a Managing Director and Investment Partner at Bay City Capital LLC. Ms. Cunicelli led Bay City Capital’s strategic advisory business since 1998, providing services to such clients as Rhone Poulenc Crop Science Division, Mallinckrodt, Monsanto and Ralston Purina. Ms. Cunicelli served on the Board of Directors of Calypso Medical Technologies, Inspired Technologies, Inc., LifeSpring Nutrition and PTC Therapeutics. Ms. Cunicelli is a Member of the Board of Trustees of Carnegie Mellon University and the University of San Francisco.